ADC Therapeutics plunges after patient deaths in blood cancer drug trial
June 4 (Reuters) – ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among treated patients, despite meeting its main goal of improving progression-free survival. The confirmatory study tested ADC’s Zynlonta along with Roche’s monoclonal antibody Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma, an aggressive, fast-growing blood cancer that affects the lymphatic […]